NCT07434518 A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
| NCT ID | NCT07434518 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Condition | Small Cell Lung Cancer (SCLC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-01-27 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2026-01-27 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the safety and efficacy of adebrelimab in the perioperative and advanced-stage treatment of small cell lung cancer （SCLC） under real-world conditions. The main questions it aims to answer are: 1. The safety of adebrelimab treatment in patients with advanced SCLC under real-world conditions, with a specific focus on the incidence of grade ≥3 immune-related adverse events. Safety monitoring begins when patients start receiving adebrelimab treatment and continues until 90 days after the last dose of adebrelimab. 2. Observe and evaluate the efficacy of adebrelimab in patients with small cell lung cancer under real-world conditions. This includes overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Additionally, the study seeks to further explore the impact of patient baseline characteristics, such as brain metastases or liver metastases, and biomarkers on prognosis.
Eligibility Criteria
Inclusion Criteria: * Histologically or cytologically confirmed extensive-stage small cell lung cancer; * Age ≥ 18 years; * The investigator determines that the patient is eligible for or is already receiving adebrelimab treatment. Exclusion Criteria: * Patients concurrently receiving other immune-modulating drugs or therapies; * Patients currently participating in other interventional studies; * Patients with concurrent other malignancies; * Patients with missing key study-related data.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07434518 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Small Cell Lung Cancer (SCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07434518 currently recruiting?
Yes, NCT07434518 is actively recruiting participants. Contact the research team at zhaoqingnan2010@126.com for enrollment information.
Where is the NCT07434518 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07434518 clinical trial?
NCT07434518 is sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.